Please login to the form below

Not currently logged in
Email:
Password:

Avastin fails colon cancer study

Roche has announced that Avastin combined with chemotherapy to treat colon cancer has failed to reach its primary endpoint in a phase III trial

Roche has announced that Avastin combined with chemotherapy to treat colon cancer has failed to reach its primary endpoint of lowering the risk of the cancer returning in a phase III trial.

The study, known as NSABP C-08, monitored the use of Avastin with chemotherapy for treatment of colon cancer after surgery compared with chemotherapy alone.

Dr Hal Barron, senior vice president, Development and chief medical officer of Genentech said: "While we are disappointed the C-08 study did not meet its primary endpoint, our initial review of the data leads us to continue to believe Avastin may be active in patients with early-stage colon cancer and look forward to NSABP's presentation at ASCO [American Society of Clinical Oncology]".

Avastin is approved in the EU for the treatment of advanced breast, lung, kidney and colorectal cancers. The results of this study do not affect the use of Avastin in advanced stages of disease.

Avastin is produced by Genentech who merged with Roche earlier this year. The cancer treatment is one of the company's key products and high sales of the drug helped to drive strong performance for Roche in Q1 2009.

23rd April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics